Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, has announced the promotion of Thomas Englese to chief commercial officer, effective immediately. Englese, who previously served as executive vice president of commercial operations since September 2024, will continue to oversee sales, marketing, market access, and commercial operations for TONMYA, the company's treatment for fibromyalgia in adults, as well as Zembrace SymTouch and Tosymra for acute migraine in adults.
The promotion comes at a pivotal time for Tonix as it works to broaden the launch of TONMYA, which was approved by the U.S. Food and Drug Administration as the first new treatment for fibromyalgia in more than 15 years. President and CEO Seth Lederman highlighted Englese's instrumental role in building Tonix's commercial organization and launching TONMYA. Englese expressed the company's focus on expanding access, growing its patient and prescriber base, and increasing sales as it broadens the TONMYA launch.
TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg) is the company's flagship medicine, designed to address a significant unmet medical need in fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties. The approval of TONMYA marked a significant milestone, offering new hope to patients who have had limited treatment options for over a decade.
Tonix's commercial infrastructure, which Englese has been instrumental in developing, supports its marketed products, including its acute migraine treatments. The company is also exploring the potential of TONMYA in other therapeutic areas, with Phase 2 clinical trials underway to evaluate its efficacy in major depressive disorder and acute stress disorder. Additionally, Tonix's pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder, and immunology programs such as TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
This leadership change signals Tonix's commitment to maximizing the commercial potential of its CNS portfolio, particularly TONMYA. The fibromyalgia market represents a substantial opportunity, and the company's strategic focus on commercial execution under Englese's leadership could drive significant growth. For patients, this means improved access to a novel treatment that may offer relief from fibromyalgia symptoms. For the industry, Tonix's progress could pave the way for further innovation in CNS disorders, where there remains a high demand for effective therapies.
The promotion of Englese to chief commercial officer reflects the company's confidence in his ability to lead commercial strategy during this critical phase. As Tonix continues to expand TONMYA's reach and develops its pipeline, the company is positioned to make a meaningful impact in the biopharmaceutical landscape.
For more information about Tonix Pharmaceuticals and its latest developments, visit the company's newsroom at https://ibn.fm/TNXP.
